| P50 | author | Jean-Jacques Kiladjian | Q37837637 |
| | Francesco Passamonti | Q42389421 |
| | Srdan Verstovsek | Q64026418 |
| P2093 | author name string | Ayalew Tefferi | |
| | Tiziano Barbui | |
| | Alessandro M Vannucchi | |
| | Animesh Pardanani | |
| | Guido Finazzi | |
| | Claire Harrison | |
| | Francisco Cervantes | |
| | Giovanni Barosi | |
| | Ronald Hoffman | |
| | Ruben Mesa | |
| | Heinz Gisslinger | |
| | Mary F McMullin | |
| | Eva Lengfelder | |
| | Jan Samuelsson | |
| | Carlos Besses | |
| P2860 | cites work | A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms | Q33390255 |
| | Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs | Q36915139 |
| | Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. | Q37412790 |
| | Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells | Q43045807 |
| | Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria | Q43061082 |
| | Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide | Q43926638 |
| | Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations | Q43979129 |
| | The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients | Q48680927 |
| | Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera | Q58416020 |
| | Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera | Q61146044 |
| | Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment | Q80866784 |
| | Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients? | Q82620294 |
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | polycythemia vera | Q948318 |
| P304 | page(s) | 4778-4781 | |
| P577 | publication date | 2013-04-16 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project | |
| P478 | volume | 121 | |